Camidanlumab, also known as HuMax-TAC, represents a cutting-edge therapeutic modality in the treatment of multiple cancers. This antibody selectively binds to TNF-alpha, a key cytokine associated in tumor https://www.targetmol.com/compound/camidanlumab